Data provided by Nasdaq. Minimum 15 minutes delayed.
October 26, 2016
NantHealth Announces Immunotherapy Clinical Trials in the Mid-Atlantic, First Whole Genomics Supercomputing Medical Reasoning Engine Helps Oncologists Make Informed Treatment Decisions for Cancer Patients
Horizon Blue Cross Blue Shield, New Jersey’s largest health insurance plan, to reimburse for GPS CancerTM comprehensive molecular test in investigational cancer studies for certain lung, breast and colon cancers The supercomputing genomics engine, a decade in the making, has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with mult...
September 21, 2016
NantHealth Partners with Children’s Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS Cancer™
GPS Cancer will allow physicians to identify personalized treatments for children with rare, refractory or recurrent cancers for whom conventional approaches have proven unsuccessful Research partnership will provide new hope for an estimated 15,780 children between the ages of birth and 19 years of age who are diagnosed with cancer each year1 CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2016-- In an effort to accelerate and improve ...
September 07, 2016
Phoenix Children’s Hospital Selects NantHealth’s Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
One of the nation’s leading pediatric hospitals to adopt GPS Cancer™, a comprehensive molecular testing platform for personalized cancer therapy, for its patients and self-insured employee population NantHealth’s decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children’s advance population health and improve value-based outcomes CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 7, 2016-- ...
|There are currently no events scheduled.|